Galactose Oral Composition for Non-Invasive Liver Function Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing liver function using galactose blood concentration require invasive intravenous injections, which are painful and stressful, especially for children, and are not suitable for non-invasive detection.
Innovation Solution
A galactose oral composition comprising D-(+)-galactose, L-(−)-galactose, stable isotope galactose, or galactose derivatives, combined with a buffer and an antioxidant, such as Vitamin C or sodium bisulfite, to create a stable and non-invasive formula that can be administered orally for detecting hepatic blood flow status, hepatic enzyme status, and galactose metabolism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If intravenous injection of galactose is used for liver function detection, then accurate detection results can be obtained, but the procedure becomes invasive causing psychological stress, tissue damage, and pain
Solution Approach 1:
The patent introduces an oral galactose solution as an intermediary substance that can be administered non-invasively. This oral solution contains galactose in a stable pH range (2.0-10.0) with antioxidants to prevent degradation, serving as a mediator between the need for accurate liver function detection and the desire to avoid invasive procedures. The oral route eliminates the need for intravenous injection while maintaining detection capability through subsequent blood sampling.
2Ease of operation
If oral galactose administration is used to avoid invasive procedures, then patient comfort improves, but the stability and accuracy of detection results deteriorates due to gastrointestinal factors
Solution Approach 1:
The patent applies parameter changes by carefully controlling the pH of the oral galactose solution within a specific range (2.0-10.0, preferably 3.0-6.0) to optimize stability. Antioxidants are added to prevent galactose degradation during gastrointestinal passage. These parameter adjustments ensure that the oral administration route maintains detection reliability comparable to intravenous methods while providing the benefits of non-invasive administration.
Solution Approach 2:
The oral galactose solution is formulated as a composite composition containing galactose, pH buffers, and antioxidants. This composite formulation ensures the stability of galactose throughout the gastrointestinal tract, maintaining its integrity for accurate liver function detection. The combination of multiple components works synergistically to preserve detection reliability while enabling non-invasive administration.
3Measurement precision
If multiple blood samples are collected for GEC testing, then comprehensive liver function assessment is achieved, but the complexity and time required for the procedure increases
Solution Approach 1:
The patent extracts the essential function of liver function detection from the complex GEC protocol that requires multiple blood samples and curve construction. By using oral galactose administration with a simplified single-point measurement approach (GSP method), the core detection capability is retained while removing the complexity of multiple sampling and curve fitting procedures. This extraction maintains comprehensive assessment capability through a streamlined protocol.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The galactose oral composition provides accurate and stable results for liver function assessment, maintaining quality through long-term storage and high-temperature sterilization, and effectively detects galactose metabolism comparable to intravenous methods without the invasive procedures.
Implementation Method 1
A galactose oral composition comprising galactose, a buffer, and an antioxidant, wherein said galactose oral composition ranges the pH values from 2.0 to 10.0
Implementation Method 2
said galactose oral composition is a food composition and/or a pharmaceutical composition... said antioxidant is selected from the group consisting of Vitamin A, Vitamin C, Vitamin E, sodium bisulfite, polyphenols, Ethylenediaminetetraacetic acid (EDTA)
Data Source
AI summary
A galactose oral composition having galactose, an antioxidant and a buffer. The galactose oral composition contains 1%-80% by weight of galactose. The antioxidant is selected from Vitamin A, Vitamin C, Vitamin E, Ethylenediaminetetraacetic acid (EDTA), sodium bisulfite, flavonoids, polyphenols, Diethylenetriaminepentaacetic acid (DTPA), and NTA-Nitrilotriacetate acid (NTA). The buffer is selected from ascorbic acid buffer, citrate buffer, phosphate buffer, acetate buffer, carbonate buffer, and triethanolamine buffer. The galactose oral composition can be applied to detect individual galactose metabolic ability to assess liver function.